SIRPA and neoplasm: Treatment with anti-CD47 antibodies can disrupt the interaction between CD47-SIRPα, allowing phagocytic clearance of tumor cells through various mechanisms: direct macrophage phagocytosis, antibody-dependent cellular cytotoxicity by natural killer cells (NK), phagocytosis and subsequent presentation of antigens by dendritic cells and / or induction of apoptosis [15–19].